MedinCell: mdc-CWM clinical phase 3 will start in 2021

March 25, 2021

MedinCell confirms that late-stage clinical trials in patients receiving intra-articular mdc-CWM at the time of Total
Knee Replacement (TKR) are planned as follows:

• The first of two phase 3 studies will start in H2 2021
• An open label safety study to supplement the mdc-CWM long-term safety database will start in Q2 2021

Injected into the intra-articular space during Total Knee Replacement surgery and potentially active for as long as three months post-surgery, mdc-CWM is a sustained-release formulation of celecoxib for the reduction of postoperative pain & inflammation

Total Knee Replacement is the first investigational indication

The mdc-CWM program development is led and financed by MedinCell’s partner, Arthritis Innovation Corporation
(AIC), who closed a $23 million CAD private equity financing in February 2021 to support clinical and manufacturing

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.